Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 15, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 380,000 ordinary shares of 25 pence each.
- Purchase Price: 1,365.9551 pence per share.
- Treasury Holdings: 113,198,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,832,483,720 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 380,000 shares on September 15, 2005, increasing its Treasury stock position. No other material changes to operations or financial condition are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the 380,000 share repurchase based on the disclosed price of 1,365.9551 pence per share.
- Confirm the updated total share count (5,832,483,720 in issue) against subsequent filings to track dilution or further buybacks.
- Review the company's broader Annual Report (Form 20-F) for comprehensive financial performance data not included in this transaction-specific filing.